New vaginitis tests can now reach patients faster, with fewer hurdles

US health regulators have reclassified devices that detect common vaginal infections, moving them to a less restrictive category. This means new tests for vaginitis and bacterial vaginosis will face a faster approval process before they can be sold.

For years, medical devices like these faced a slow, expensive approval process designed for high-risk products. This change means that manufacturers of these specific diagnostic tests can bring them to market more quickly and at a lower cost. The goal is to get new, beneficial diagnostic tools to patients faster, especially for common conditions that affect many people.